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Abstract
Background: Our previous studies showed a down-regulation of GRIM-19 in primary human cervical cancers, and
restoration of GRIM-19 induced tumor regression. The induction of tumor suppressor protein p53 ubiquitination and
degradation by E6 oncoportein of high risk-HPV through forming a stable complex with E6AP is considered as a critical
mechanism for cervical tumor development. The aims of this study were to determine the potential role of GRIM-19 in
rescuing p53 protein and inducing cervical cancer cell apoptosis.
Methodology/Principal Findings: The protein levels of GRIM-19 and p53 were detected in normal cervical tissues from 45
patients who underwent hysterectomy for reasons other than neoplasias of either the cervix or endometrium, and cervical
cancer tissues from 60 patients with non-metastatic squamous epithelial carcinomas. Coimmunoprecipitation and GST pull-
down assay were performed to examine the interaction of GRIM-19 with 18E6 and E6AP in vivo and in vitro respectively. The
competition of 18E6 with E6AP in binding GRIM-19 by performing competition pull-down assays was designed to examine
the disruption of E6/E6AP complex by GRIM-19. The augment of E6AP ubiquitination by GRIM-19 was detected in vivo and
in vitro ubiquitination assay. The effects of GRIM-19-dependent p53 accumulation on cell proliferation, cell cycle, apoptosis
were explored by MTT, flow cytometry and transmission electron microscopy respectively. The tumor suppression was
detected by xenograft mouse model.
Conclusion/Significance: The levels of GRIM-19 and p53 were concurrently down regulated in cervical cancers. The
restoration of GRIM-19 can induce ubiquitination and degradation of E6AP, and disrupt the E6/E6AP complex through the
interaction of N-terminus of GRIM-19 with both E6 and E6AP, which protected p53 from degradation and promoted cell
apoptosis. Tumor xenograft studies also revealed the suppression of p53 degradation in presence of GRIM-19. These data
suggest that GRIM-19 can block E6/E6AP complex; and synergistically suppress cervical tumor growth with p53.
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Introduction
High-risk human papillomaviruses (HR-HPV), such as HPV18
and HPV16, is not only an important cause of cervical cancer [1],
but also the pathogens of a subset of other tumors such as head
and neck squamous carcinomas [2], lung cancer [3] upper
aerodigestive tract cancer [4] and anogenital cancer [5]. The
expression of viral oncoproteins E6 in HPV-positive cervical
carcinomas [6] can interact with the E6-associated protein (E6AP)
to form E6/E6AP complex that specifically induces the ubiqui-
tination and rapid degradation of p53, nuclear transcription factor
X-box binding 91 (NFX1-91) and PDZ domain-containing
proteins through the proteasome pathway [7,8,9,10]. p53
degradation is an essential requirement for the survival of HR-
HPV-infected tumors; thus blocking E6/E6AP complex mediating
p53 degradation may be an attractive approach for treating
cancers with HR-HPV infection [11,12,13,14].
GRIM-19 was originally identified as a tumor-suppressive
protein that was involved in cell death [15] through the association
and suppression of STAT3 [16,17]; Its expression is down
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22065regulated in renal, prostate and cervical cancers [16,17,18,19,20].
Moreover, GRIM-19 suppresses oncogene-induced remodeling of
cytoskeleton and cell motility [21]; and cell cycle progression by
interacting with tumor suppressor p16Ink4a [22]. Thus, GRIM-19
exerts distinct mechanisms in a variety of cell types. Here we
report that GRIM-19 induces p53 accumulation through a
disruption of the E6/E6AP complex and an induction of auto-
ubiquitination of E6AP in cervical cancer cells. This study
demonstrates a novel function and a molecular mechanism by
which GRIM-19 inhibits HR-HPV induced tumorigenesis by
protecting p53 from degradation.
Results
GRIM-19 and p53 are concurrently downregulated in
cervical cancers
Our previously study demonstrated that GRIM-19 induces
cervical tumor regression in a mouse xenograft model, suggesting a
possible role of GRIM-19 in tumor growth regulation [20]. Since
p53 tumor suppressor is also low expressed in cervical tumors, we
further examined if there is a correlation between the levels of
GRIM-19 and p53. The levels of GRIM-19 and p53 were
significantly (p,0.01) lower in the tumors, and directly correlated
with each other in .99% of cervical tumors (Fig. 1). Consistent
with a low p53 in the tumors, a well-studied p53 target gene,
PUMA, was also downregulated in the tumors compared to
normal tissues (Fig. 1). These results demonstrated that GRIM-19
and p53 levels were concurrently suppressed, suggesting a
potential link between GRIM-19 and p53 in cervical cancer.
GRIM-19 augments p53 protein levels in cervical tumor
cells
To further investigate the relationship between GRIM-19 and
p53, HeLa cells with either overexpression (pG19) or knockdown
(siG19) of GRIM-19 were used, and the levels of GRIM-19 and
p53 were evaluated by Western blotting (Figure 2A). Interestingly,
when compared to the corresponding control (p/siCon) cells, p53
and its target genes PUMA and p21 increased in HeLa/pG19 cells
(Fig. 2A, left panels) and decreased in HeLa/siG19 cells
(Figure 2A, right panels). In addition, two other cervical cancer
cell lines, SiHa and CaSki, were transfected with either a GRIM-
19 expression plasmid or dsRNA targeting GRIM-19 and
compared to their respective controls. Results similar to those
observed in HeLa were obtained in these cells too (Fig. 2B).
Moreover, tests on other HPV-free tumor cell lines (A549 and
HO8910) didn’t reveal the same results as observed in HeLa (Fig
S1). Thus, the levels of GRIM-19 directly correlated with those of
p53 in cervical cancer cells.
To investigate whether GRIM-19 increased p53 via transcrip-
tional regulation, p53 mRNA levels were examined by quantita-
tive RT-PCR and luciferase reporter assay were performed in
HeLa/pCon and HeLa/pG19 cells. The level of p53 mRNA was
unaffected by overexpression of GRIM-19 (Fig. 2C). Additionally,
p53 promoter-driven luciferase reporter did not reveal significant
changes in p53 promoter activity in HeLa/pCon and HeLa/pG19
cells (Fig. 2D), suggesting that GRIM-19 is not involved in the
transcriptional activation of p53.
In cervical tumors, p53 is infrequently mutated [23], and it is
rapidly degraded by E6/E6AP [6,24], we next examined whether
increase in p53 levels is due to enhanced half-life of the protein.
HeLa/pG19 and HeLa/pCon cells were treated with cyclohex-
imide and p53 protein levels were monitored over time. Indeed,
the half-life of p53 protein was significantly (p,0.01) prolonged in
HeLa/pG19 cells compared to HeLa/pCon cells (Fig. 2E). In vivo
ubiquitination assay also showed that ubiquitinated p53 in HeLa/
pG19 cells was dramatically reduced compared to HeLa/pCon
cells (Figure 2F).
Taken together, these results suggested that GRIM-19 restored
p53 levels through protein stabilization rather than transcriptional
up-regulation in cervical tumors.
GRIM-19 stabilizes p53 protein by interacting with E6 and
E6AP proteins
E6/E6AP-mediated p53 degradation is considered as an
important mechanism in initiation and development of cervical
carcinomas [23,25]. Since GRIM-19 binds to 16E6 [26], we
hypothesized that GRIM-19 interferes with E6/E6AP complex,
thereby protecting p53 from degradation. Using immunoprecip-
itation assays with cellular lysates from HeLa cells, we found the
interaction of GRIM-19 with E6AP in vivo (Fig. 3A). We then
examined the GRIM-19-E6AP interaction in vitro with GST pull-
down assays. E6AP encodes three different protein isoforms (I, II
and III) that differ in their N terminal tails, all of which have the
ability to stimulate E6-mediated ubiquitin-dependent degradation
Figure 1. A correlation between the loss of GRIM-19 and p53 proteins in primary cervical cancers. (A) Total cellular extracts (50 mg) from
primary cervical tumors (T) and normal cervical tissues (N) were examined for the expression of GRIM-19, p53 and PUMA by Western blotting. The
representative results of Western blotting are shown. T1-T4 was from individual patients with cervical cancer. T1 and T2 were diagnosed as stage IIa;
and T3 and T4 were diagnosed as stage Ia squamous epithelial carcinomas. (B) Quantitative analysis of the protein expression as measured by the
optical density of each band. The ratio of the density from GRIM-19, p53, PUMA over the corresponding GAPDH (45 cases of normal tissue and 60
cases of tumor tissue) was calculated.
doi:10.1371/journal.pone.0022065.g001
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22065Figure 2. GRIM-19 induced p53 protein accumulation in HR-HPV infected cervical tumor cells. (A&B ) The protein levels of GRIM-19 and
p53 in primary cervical cancers. Western blotting with the indicated antibodies was performed using lysates from the indicated cell lines. (C) Effect of
GRIM-19 on p53 mRNA expression. The mRNA of GRIM-19 (left panel) significantly high in HeLa/pG19 cells (* p,0.01), the right panel shows p53
mRNA expression. Differences are not statistically significant. (D) GRIM-19 did not affect the p53-promoter activity. A p53-Luc reporter was used. The
data presented are the mean of three independent experiments with triplicate samples in each test. (E) GRIM-19 increases the half-life of p53. Cells
were treated with CHX (100 mg/ml) for the indicated time periods and lysates were subjected for Western blotting with the indicated antibodies.
Representative results from one out of three independent experiments are shown (left panel). The remaining value for p53 was calculated as the ratio
of the densitometric values of p53 over GAPDH in each sample (right panel). The average remaining values from three independent experiments
were plotted. (F) GRIM-19 inhibited p53 degradation in vivo. Before harvesting the cells were treated with MG132 for 4 h, and immunoprecipitation
with p53 antibody was performed. Western blotting of the IP products was using ubiquitin antibody. GAPDH antibodies were used to determine the
comparable loading.
doi:10.1371/journal.pone.0022065.g002
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had been previously identified [28], we generated three recom-
binant plasmids expressing His-tagged E6AP-III isoform-based
deletions: pE6AP-D1 (1–286 aa), pE6AP-D2 (287–521 aa) and
pE6AP-D3 (522–872 aa). E6 binding sites were located between aa
287–521 of E6AP-III, while the HECT domain for ubiquitin
binding sites was located in the segment from 522–872 aa (Fig. 3C)
[29]. We found that only E6AP-D3 bound to GST-tagged GRIM-
19 by GST pull-down assay (Fig. 3B–C), but not the catalytically
inactive E6AP containing a mutation on Cys at position 840 (Fig
S2), These results supported our conclusion that GRIM-19 can
bind the HECT domain of E6AP. To map the exact interacting
region of GRIM-19 with E6AP, we employed GST-tagged
GRIM-19 deletions pGST-G19-D1, pGST-G19-D2 and pGST-
G19-D3; And found that amino acids 1–35 of GRIM-19 were
sufficient for binding E6AP proteins (Fig. 3D).
We have reported the interaction of GRIM-19 with 16E6
before [26], we then explored the association of GRIM-19 and
18E6. Due to the low expression of E6 and poor reactivity of
available E6 antibodies that have been reported by a number of
publications [30,31,32,33], we failed to obtain a satisfactory 18E6
Western blot from the cell lysates. Therefore, a plasmid p18E6-
Flag that expresses a Flag-tagged 18E6 protein was constructed.
Through Immunoprecipitation assays in HeLa cells transfected
with p18E6-Flag, we found 18E6 co-precipitated with GRIM-19 in
vivo (Fig. 3E). To map the exact interacting region of GRIM-19
with 18E6, we employed the binding site of GRIM-19 with 18E6
by using GST-tagged GRIM-19 deletions (pGST-G19-D1, pGST-
G19-D2 and pGST-G19-D3); And found that amino acids 1–35 of
GRIM-19 were sufficient for binding 18E6 proteins in vitro
(Fig. 3F).
We therefore concluded that GRIM-19 can bind both 18E6 and
E6AP in vivo and in vitro, which might play a role in accumulation
p53 protein.
GRIM-19 disrupts E6/E6AP complex and augment E6AP
ubiquitination and degradation
Given that both 18E6 and E6AP-D3 can interact with amino
acids 1–35 of N terminus of GRIM-19 (Fig. 3G), we determined
whether 18E6 competed with E6AP in binding GRIM-19 by
performing competition pull-down assays. In the presence of
purified GST-G19 protein and increasing amount of E6AP-D3,
the binding of 18E6 to GRIM-19 progressively decreased as
E6AP-D3 increased (Fig. 4A). Although E6AP-D2 failed to interact
with GST-G19, it is well known that this region harbors E6-
binding sites [28]. Therefore, we tested whether GST-G19 and
E6AP-D2 compete in binding with 18E6. In the presence of E6AP-
D2, GST-G19-bound 18E6 decreased compared to 18E6
presented alone (Fig. 4B). Furthermore, we did not observe an
association of E6AP-D2 with GST-G19 in the presence of 18E6,
suggesting that the proteins cannot form a heterotrimeric complex
of 18E6/E6AP-D2/GST-G19.
It has been well established that E6AP can target itself for
ubiquitination, which represents a mechanism to control its own
half-life [7,34]. We then explore if the expression of GRIM-19 can
influence the degradation of E6AP, in the presence of overex-
pressed GRIM-19, ubiquitinated E6AP significantly increased
compared to HeLa/pCon cells (Fig. 4C). In vitro ubiquitination
assay showed that GRIM-19 increased the autoubiquitination of
wild-type E6AP, but not its dominant-negative CA mutant by
using purifed E1 and E2 (UbcH5c), bacteria-expressed GRIM-19,
and wild-type E6AP and CA mutant E6AP translated in wheat
germ extract system (Fig. 4D). Indeed, we found E6AP protein was
decreased in cells with overexpression GRIM-19 (Fig. 4E, S1).
In summary, we conclude that GRIM-19 prevents p53
degradation by impeding E6/E6AP complex formation and
promotes ubiquitination and degradation of E6AP.
GRIM-19 delays G0/G1 transition, inhibits cell
proliferation and induces apoptosis, and promoted p53
accumulation in vivo
Given that inductions of cell cycle arrest and cell growth
suppression are the major functions of p53, we next evaluated the
effect of GRIM-19-dependent p53 stabilization on cell cycle. Cell
cycle distribution analyses revealed a significantly delayed G0/G1
transition in HeLa/pG19 cells when compared to HeLa/pCon
cells (Table 1). Additionally, as indicated by MTT assay, the cell
proliferation of HeLa/pG19 cells was significantly (p,0.05)
suppressed on day 3 and day 4 (Fig. 5A) compared to HeLa/
pCon cells.
Because promoting cell apoptosis is another key function of p53,
we performed cell apoptosis assays including transmission electron
microscopy (TEM) and Western blotting with caspase 3 and PARP
antibodies. A range of early apoptosis characteristics were
indicated in HeLa/pG19 cells, including nuclear chromatin
condensation, widened nuclear membrane gap, vague nuclear
membrane structure, fractures of nuclear membrane and endo-
plasmic reticulum expansion; however, these phenomena were not
observed in HeLa/pCon cells (Fig. 5B arrows). In addition, the
cleavage of caspase 3 and PARP was increased in HeLa/pG19
cells compared to HeLa/pCon cells (Fig. 5C).
We also found the tumor weights in the mice transplanted with
HeLa/pG19 cells was significantly reduced compared to those of
control groups (p,0.05) (Fig. 5D). GRIM-19 and p53, together
with p21, PUMA and p27 proteins were significantly increased,
but E6AP was decreased in the tumors derived from HeLa/pG19
cells compared to tumors from HeLa/pCon cells (Fig. 5E).
Finally, based on our observations, a model for GRIM-19
induced cell apoptosis by disrupting the E6/E6AP complex and
stabilizing p53 was speculated (Fig. 5F). This model suggests that
the presence of GRIM-19 promotes auto-ubiquitination and
degradation of E6AP by interacting with these proteins and
contributes to p53 stabilization, growth arrest and apoptosis.
Discussion
High-risk human papillomaviruses (HR-HPV), such as HPV18
and HPV16, are associated with 99.7% of cervical cancers [35],
which are the most common gynecologic tumors in developing
countries [36]. The viral oncoproteins E6 and E7 are expressed in
HPV-positive cervical carcinomas [6], while the viral E2 protein
represses transcription of the E6/E7 oncogenes and activates viral
DNA replication together with the viral E1 helicase [37,38,39].
The E6/E6AP mediated degradation of p53 is considered a most
important mechanism in the initiation and development of cervical
cancers [6,11,12,25,40,41]. Recent studies suggested that interfer-
ence of the E6/E6AP complex may kill cervical tumors by
increasing the level of p53 protein [11,12,40]. In our study, we
present a new approach to prevent p53 degradation by restoration
of GRIM-19 that disrupts the E6/E6AP complex.
It has been reported that GRIM-19 can suppress transcriptional
activity of STAT3 through protein-protein interaction, and inhibit
cancer growth [16,17]. STAT3 has been shown to inhibit p53
expression via a transcriptional repression in the src oncogene-
induced signaling pathways in certain rodent cell lines [42]. Some
studies in cancer cell lines showed a correlation between high
constitutive STAT3 activity and p53 gene mutations, although the
cause and effect relationships were not established [43]. In certain
GRIM-19 Disrupts E6/E6AP Complex to Rescue p53
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shown down regulate NF-kB and STAT3 induced gene expression
[44]. We have shown in our previous publication that GRIM-19
loss correlates with a high STAT3 activity in primary cervical
cancers [20]. Although such observations suggest a possibility that
loss of GRIM-19 promotes high STAT3 activity which could
ultimately transcriptionally down regulate p53 expression, our
studies did not reveal (fig. 2C &D) any changes in the expression of
Figure 3. GRIM-19 bound to 18E6 and E6AP protein in vivo and in vitro. (A) Co-immunoprecipitation assays were performed to determine
the interaction between GRIM-19 with E6AP in vivo. The cell lysates from HeLa cells were immunoprecipitated with normal IgG and anti-GRIM-19
antibodies and Western blotted with anti-E6AP. Input (preIP) lane represents 10% of the extract used in the immunoprecipitation reaction. HC=IgG
heavy chain. (B) GST pull-down experiments were performed to examine the interaction of His-tagged E6AP deletions with GST-fused GRIM-19
protein in vitro.( C) Schematic diagram of E6AP indicating various functional domains including the binding sites for GRIM-19. (D) The interaction of
GST-GRIM-19 deletions with E6AP. * indicates the position of the band with correct molecular size. (E) Co-immunoprecipitation assays were
performed to determine the interaction between GRIM-19 with 18E6. The cell lysates from HeLa cells transfected with the p18E6-Flag were subjected
to IP with the indicated antibodies. Input (preIP) lane represents 10% of the extract used in the immunoprecipitation reaction. LC=IgG light chain. (F)
The interaction of GST-GRIM-19 deletions with 18E6. * indicates the position of the band with correct molecular size. (G) Deletion mapping of the E6
or E6AP binding sites on the GRIM-19.
doi:10.1371/journal.pone.0022065.g003
GRIM-19 Disrupts E6/E6AP Complex to Rescue p53
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endogenous p53 mRNA. Therefore, STAT3 deregulation may not
have a direct consequence on p53 expression in our model.Thus, two
GRIM-19independentpathways:1)anactivationofSTAT3and2)a
down regulation of p53 concurrently occur in HPV transformed
cervical carcinomas for promoting tumorigenesis following the loss of
GRIM-19 expression. More importantly, Interference with STAT3
expression using RNAi or its function using dominant negative
approaches (Fig S3) did not significantly alter the GRIM-19 effects on
p53 stabilization. Therefore, p53 protein stabilization by GRIM-19
appears to occur independently of STAT3.
In this paper, we also tested whether GRIM-19 inhibits p53
degradation in the absence of E6. Two HPV negative cells
HO8910 and A549 that both containing wild-type p53 [45] were
examined for their p53 expression after overexpression of GRIM-
19. Although GRIM-19 was able to augment the degradation of
E6AP in these two cells, the protein levels of p53 remained
unchanged (Fig S1), suggesting that GRIM-19 is able to prevent
E6-dependent p53 degradation.
Recent reports have demonstrated that GRIM-19 can interact
with some other important physiological proteins such as HtrA2
[46]; Moreover, viral proteins such as U95 and vIRF1 can also
Figure 4. GRIM-19 disrupted E6/E6AP complex and augment E6AP ubiquitination and degradation. (A) Competitive assays were
performed to analyze the binding of 18E6 to GST-GRIM-19 fusion protein in presence of increasing amounts of E6AP-D3 ranging from 0–6 mg. (B)
Pull-down experiments to determine the binding of 18E6 to GST-GRIM-19 proteins. Where indicated E6AP-D2 proteins (10 ug) were added into GST
Pull-down reaction. (C) GRIM-19 augmented E6AP degradation in vivo. Before harvesting the cells were treated with MG132 for 4 h, and
immunoprecipitation with E6AP antibody was performed. Western blotting of the IP products was using ubiquitin antibody. GAPDH antibodies were
used to determine the comparable loading. (D) In vitro E6AP ubiquitination assay. Human recombinant ubiquitin, E1, E2 (UbcH5c), batereria-
expressed and purified GST and GTS-GRIM-19, E6AP (wild-type or catalytically inactive mutant CA) from wheat germ extract were mixed for in vitro
E6AP ubiquitination assay and immunoblotted with ubiquitin antibody. (E) Whole cell lysates from HeLa cells expressing the indicated expression
plasmids were Western blotted with the indicated antibodies.
doi:10.1371/journal.pone.0022065.g004
Table 1. GRIM-19 delayed G0/G1 transition.
Cells Phase/stage Time (h)
04681 0 1 4
HeLa/pCon G0/G1 55.54 12.27 10.55 15.50 12.05 72.15
S 38.53 70.90 51.22 46.30 48.82 7.80
G2/M 5.93 16.83 38.23 38.20 39.13 20.05
HeLa/pG19 G0/G1 60.20 25.71 18.25 17.66 17.95 66.12
S 32.80 58.59 49.37 48.01 48.75 7.86
G2/M 7.00 15.70 32.38 34.33 33.30 26.02
doi:10.1371/journal.pone.0022065.t001
GRIM-19 Disrupts E6/E6AP Complex to Rescue p53
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22065Figure 5. GRIM-19 inhibited cell proliferation and induced apoptosis, and promoted the accumulation of p53 in tumors. (A) An MTT
assay was performed in the indicated cells. MTT assay was performed as in Materials and Methods. Each data point represents the mean 6 SE of 8
samples. (B) The morphological characteristics of HeLa/pCon and HeLa/pG19 cells were examined by transmission electron microscopy. Chromatin
condensation, expansion and widened nuclear membrane gaps, vague nuclear membrane structure, fractures of nuclear membrane and endoplasmic
reticulum expansion were indicated with arrows. ER, endoplasmic reticulum; NM, nuclear membrane. (C) The full length and cleaved form of caspase-
3 and PARP in HeLa/pCon and HeLa/pG19 cells were determined by Western blot analyses. (D) HeLa/Con and HeLa/G19 cells were transplanted into
6-week-old female athymic nude mice (10 mice for each cell line) and grown for 6 weeks. Tumors were harvested, and weights were measured. The
data present the mean of 10 tumors in each group. (E) The expression of GRIM-19, p53, p21, PUMA, p27 and E6AP in the tumors derived from mice as
determined by Western blot analyses, and the representative results are presented. (F) A model for the collaboration between GRIM-19 and p53.
When GRIM-19 is present in high levels, it interacts with the E6/E6AP complex, promotes their ubiquitination, thus, preventing p53 degradation. The
loss of GRIM-19 allows the attack of E6/E6AP complex on p53 and its degradation through the proteasome.
doi:10.1371/journal.pone.0022065.g005
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22065bind to GRIM-19 [21,26,47]. We have previously shown an
association between 16E6 and GRIM-19 [26]; here, we also found
the interaction of GRIM-19 with 18E6 and E6AP in vivo and in
vitro, and the induction of the autoubiquitination degradation of
E6AP by GRIM-19. In HR-HPV infection cervical cancer cells,
GRIM-19 was able to induce accumulation of the p53 protein and
to increase p53 target genes such as p21 and PUMA. Additionally,
significant changes on the cell cycle profile, cell proliferation, and
the characteristic morphological signs of apoptosis were observed
in HeLa cells overexpression of GRIM-19. Thus, GRIM-19 and
p53 can synergistically suppress cervical cancer cell growth.
E6AP is a critical regulator of p53 degradation in human
cervical cancers in an E6 dependent manner. Apart fromp53, E6/
E6AP complex has been reported to interfere with several cellular
functions [48] including transcriptional activators such as IRF3,
co-activators such asp300, apoptosis inducers such as Bak,
GADD34, procaspase-8 and its adaptor FADD, protein kinases
such as tyk2, cell adhesion associated molecules such as Paxillin,
and NFX1-91, a molecules that attenuates telomerase activity. In
most of these cases the E6/E6AP complex targets these proteins to
degradation to allow oncogenic transformation [48]. E6 interac-
tion with E6AP has been reported to be important for skin
carcinogenesis in transgenic mouse models [49,50]. E6AP also
targets proteins in an E6-independent manner. In fact, several
substrates such as members of the Src family of protein kinases
[51], polycomb protein Ring1B [52] and the promyelocytic
leukemia (PML) protein [53] have been reported. Naturally
occurring sporadic E6AP mutations are associated with Angel-
man’s syndrome, a severe form of mental retardation, wherein
accumulation of undegraded protein aggregates has been reported
[52,54,55,56]. Thus, E6AP protein in association with E6 and in
some situations on its own plays a central role in protein
degradation controlling several human pathologies.
Because E6AP also acts as a dual function coactivator for steroid
hormone receptors (SHRs) including progesterone receptor, estrogen
receptor, androgen receptor, glucocorticoid receptor, retinoic acid
receptor-a and thyroid hormone receptor [29,57], and the amino
acids from 170–680 are the activation domain of E6AP [29], the
interaction of GRIM-19 with E6AP (522–872 aa) might predict that
GRIM-19 probably regulates SHR-dependent gene transcription.
In summary, our studies for the first time show a novel
mechanism by which GRIM-19 blocks E6/E6AP complex; and
the collaboration between two distinct tumor suppressor proteins
in regulating cell growth.
Materials and Methods
Ethics Statement
All cervical tissues were obtained from patients who underwent
hysterectomy between January 2008 and November 2009 at
Anhui Provincial Hospital affiliated to Anhui Medical University,
Hefei, China. The study was reviewed and approved by the ethics
review board of Anhui Provincial Hospital. Written consent was
obtained from each patient.
All animal experimental procedures carried out in this study
have been approved by the Laboratory Animal of the Ethics
Committee of Anhui Provincial Hospital Affiliated to Anhui
Medical University under permit number 201000179, and were in
compliance with the guidelines for animal care set forth by this
Committee.
Tumors
A portion of freshly-excised tissues were paraffin-embedded, cut
into 5- to 7-mm-thick sections for pathologic diagnosis, and the rest
of the tissue was frozen at 280uC for further use to extract
proteins and RNA. Clinical stages were determined by a certified
gynecologic pathologist according to a modified International
Federation of Gynecology Obstetrics (FIGO) staging system for
cervical cancer in 2000. The 60 non-metastatic squamous
epithelial carcinomas examined in these studies were HPV16 or
HPV18 positive and belonged to type Ia (13 patients), Ib (9
patients) and IIa (38 patients). Additionally, 45 normal cervical
tissues from patients who underwent hysterectomy for reasons
other than neoplasia of either the cervix or endometrium were
collected and used as normal controls in this study.
Cell culture and transfection
Human cervical cancer cell lines HeLa, SiHa and CaSki and
the human lung adenocarcinoma cell line A549 from American
Type Culture Collection (ATCC) were grown DMEM with 10%
fetal bovine serum. The human ovarian cancer cell line HO8910
was purchased from cell bank of the Chinese Academy of Sciences
[58,59] and grown in complete RPMI-1640. Lipofectamine 2000
(Invitrogen) was used for transfection. The stably transfected cell
lines HeLa/pCon and HeLa/pG19 expressing control vector and
human GRIM-19, respectively, were described previously [20].
Tumor xenografts
Animals were reared under standard laboratory conditions.
Two groups (10 in each group) of 6-week-old female athymic nude
mice (Beijing experimental animal center) were implanted
subcutaneously on the right flank of mice with either HeLa/
pG19 or HeLa/pCon cells (1610
7) in 0.1 ml PBS containing 50%
matrigel. All mice were housed in a pathogen-free environment.
At the end of the experiment (6 weeks after implantation), mice
were euthanized, tumors were collected and weighed. A portion of
each tumor was processed for immunohistochemical and bio-
chemical analyses, and the rest was frozen at 280uC until use.
Plasmids
The plasmids LZRSpBMN-linker-IRES-EGFP-STAT3C
(STAT3C) expressing a constitutively active mutant STAT3 and
LZRS pBMN-linker-IRES-EGFP-STAT3DN (STAT3DN) ex-
pressing a dominant negative mutant STAT3 were gifts from
Dr. Hodge DR as described previously [60]. The empty vector
pIRES-Puro2-Myc (pCon) and pIRES-Puro2-GRIM-19-Myc
(pG19) expressing a Myc-tagged GRIM-19 were described
previously [20]. The luciferase reporter pGL3-P53-Luc containing
a 676-bp human p53 promoter sequence from 229 bp to
2704 bp of the ATG start site was PCR amplified with human
genome DNA (Invitrogen) by using a sense primer with a SacI
restriction enzyme site (underlined) 59-GAGCTCCAACAAT-
GAATAAGATACTAG-39 and an antisense primer with a BglII
restriction enzyme site (underlined) 59-AGATCTCAATCCAGG
GAAGCGTGTCAC-39 and was subsequently ligated into SacI/
Bgl II-double digested pGL3-basic vector (Promega).
To construct a plasmid expressing a wild-type HPV18 E6
protein tagged with Flag, the coding sequences were amplified
with genome DNA from HeLa cell as template (GeneBank
Accession: X05015) by a primer pair: a sense primer with an
HindIII restriction enzyme site (underlined): 59-CCCAAGCTTG
CGCGCTTTGAGGATCCAA-39; and an antisense primer with
a KpnI restriction enzyme site (underlined): 59-CGGGGTACCT-
TATA CTTGTGTTTCTCTGCGTCG-39. The PCR products
were inserted into a HindIII/KpnI -digested p36Flag-Myc-
CMV
TM-24 vector (Sigma). The resulted clone was designed as
p18E6-Flag.
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HPV18 E6 protein, p18E6-Flag was used as the template and
PCR amplified with the primer pair: a sense primer with an NdeI
restriction enzyme site (underlined): 59-GGGAATTCCATATG-
GACTACAAAGACCATGA CGG-39; and an antisense primer
with a Xhol restriction enzyme site (underlined): 59-CCG-
CTCGAGTTATACTTGTGTTTCTC TGCGTCG-39. The
PCR products were inserted into an NdeI/Xhol-digested pET-
22b vector (Novagen) and the resulted plasmid was designed as
pET-18E6-Flag.
To construct the bacterial recombinant plasmid expressing His-
tagged wild-type E6AP protein, the coding sequence of E6AP
was PCR amplified using pCMV6-XL5-E6AP-III (Origene,
SC120518, USA,) as a template with the following primer pair:
a sense primer with an NdeI restriction enzyme site (underlined):
59-GGGAATTCCATATGGCCACAGCTTGTAAAAGA TCA-
GG -39; and an antisense primer with a HindIII restriction enzyme
site (underlined): 59-CCCAAGCTTCA GCATGCCAAATC-
CTTTGG -39. The PCR products were inserted into an NdeI/
HindIII -digested pET-22b vector (Novagen), and the resulted
plasmid was designed as pET-E6AP-his.
By using pET-E6AP-his as the template, the E6AP deletions
were PCR-amplified to construct the truncated His-tagged E6AP-
expressing vectors (Figure 3C). The primers for pE6AP-D1 (1–
286 aa): a sense primer with an NdeI restriction enzyme site
(underlined): 59-GGGAATTC CATATGGCCACAGC TTGT-
AAAAGA TCAGG -39; and an antisense primer with a HindIII
restriction enzyme site (underlined): 59-CCCAAGCTTGATAAT-
GAACAAATTCAGA -39. The primers for pE6AP-D2 (287–
521 aa) were: a sense primer with an NdeI restriction enzyme site
(underlined): 59-GGGAATTC CATATGGTAATGGAGAATA-
GAAATCTCC-39; and an antisense primer with a HindIII
restriction enzyme site (underlined): 59-CCCAAGCTTTCTCAA
ATATGGATTCAACT-39. The primers for pE6AP-D3 (522–
872 aa) were: a sense primer with an NdeI restriction enzyme site
(underlined): 59-GGGAATTCCATATGCTCAAAG TTAGAC-
GTGACCA-39; and an antisense primer with a HindIII restriction
enzyme site (underlined): 59-CCCAAGCTTCAGCATGCC AA-
ATC CTTT-39. The PCR products were inserted into an NdeI/
HindIII -digested pET-22b vector.
To construct the bacterial recombinant plasmid expressing
GST-tagged GRIM-19, the coding sequences were PCR amplified
using pIRES-Puro2-GRIM-19-Myc as a template with the
following primer pair: a sense primer with a BamHI restriction
enzyme site (underlined): 59-CGCGGATCCGCGGCGTC AAA-
GGTGAAG -39; and an antisense primer with an Xhol restriction
enzyme site (underlined): 59-CCGCTCGAGCTACGTGTAC-
CACATGAA GCC -39. The PCR products were inserted into a
BamHI/Xhol -digested pGEX-4T-3 vector (GE Healthcare,
Piscataway, NJ, USA) to construct pGST-G19.
By using pGST-G19 as a template, GRIM-19 deletions were
PCR-amplified to construct the truncated GRIM-19-expressing
vector. The primers for pGST-G19-D1 (1–35 aa): a sense primer
with a BamHI restriction enzyme site (underlined): 59- CGC-
GGATCCGCGGC GTCAAAGGTGAAG -39, and an antisense
primer with an XhoI restriction enzyme site (underlined): 59-
CCGCTCGAGCTACATGCTGTAGCCCGA -39. The primers
for pGST-G19-D2 (36–70 aa) were: a sense primer with a BamHI
restriction enzyme site (underlined): 59- CGCGGATCCCTGGC-
CATAGGGATTGGAA -39, and an antisense primer with an
XhoI restriction enzyme site (underlined): 59- CCGCTCGAGC-
TACGCGATGCGAGCCT -39. The primers for pGST-G19-D3
(71–144 aa) were: a sense primer with a BamHI restriction
enzyme site (underlined): 59- CGC GGATCCCTGTTGC-
CACTGTTACAGGC AA-39; and an antisense primer with an
XhoI restriction enzyme site (underlined): 59- CCGCTCGAGC-
TACGTGTACC ACATGAAGCC -39. The PCR products were
inserted into a BamHI/XhoI-digested pGEX-4T-3 vector. All of
the plasmids were confirmed by DNA sequencing.
To construct a plasmid encoding a catalytically inactive mutant
E6AP-III, plasmids of pGEX-2T-E6AP-I C833A (provided by Dr.
Peter Howley, Harvard Medical School, Boston, MA) and
pCMV6-XL5-E6AP-III were used as templates, and the sequences
for E6AP-III mutant were amplified with primer pairs: a sense
primer with a BamHI restriction enzyme site (underlined): 59-
CGCGGATCCGCCACAGCTTGTAAAAGA TCAGG -39; and
an antisense primer with an Xhol restriction enzyme site
(underlined): 59-CCGCTCGAGTCTCAAATATGGATTCAA-
CT -39; another sense primer with a BamHI restriction enzyme
site (underlined): 59-CGCGGATCC CTCAAAGTTAGACGT-
GACCA -39; and another antisense primer with an XhoI
restriction enzyme site (underlined): 59-CCGCTCGAG CAG-
CATGCC AAATC CTTT -39. The PCR products were inserted
into a BamHI/XhoI -digested pGEX-4T-3 vector (GE Health-
care), and the recombinant plasmid was named as pGST-CA-
E6AP.
To construct a plasmid encoding catalytically inactive mutant
E6AP-III with T7 promoter for in vitro translation, the mutant
E6AP-III sequence was PCR amplified using pGST-C840A-E6AP
as a template with the following primer pair: a sense primer with
an NdeI restriction enzyme site (underlined): 59-GGGAATTC-
CATATGGCCACAGCTTGTAAAAGATCAGG -39; and an
antisense primer with a HindIII restriction enzyme site (under-
lined): 59-CCCAAGCTTCAGCA TGCCAAATCC TTTGG -39.
The PCR products were inserted into an NdeI/HindIII-digested
pET-22b vector (Novagen), and the recombinant plasmid was
named as pET- CA -E6AP.
To construct the bacterial recombinant plasmid expressing
Flag-tagged GRIM-19, the coding sequences were PCR ampli-
fied using pIRES-Puro2-GRIM-19-Myc as a template with the
following primer pair: a sense primer with a HindIII restriction
enzyme site (underlined): 59-CCCAAGCTTCAAG AACCAA-
GGCGAGTCA-39; and an antisense primer with a BamHI
restriction enzyme site (underlined): 59-CGCGGATCCTACG-
TGTACCACATGAAGCCG-39. The PCR products were insert-
ed into a HindIII/BamHI-digested p36Flag-Myc-CMV
TM-24
vector to construct pGRIM-19-Flag. Then pET-GRIM-19-Flag
was amplified using pGRIM-19-Flag as a template with the
following primer pair: a sense primer with a NdeI restriction
enzyme site (underlined): 59-GGGAATTCCATATGGACTA
CAAAGACCATGACGG-39; and an antisense primer with a
HindIII restriction enzyme site (underlined): 59-CCCAAGCTTC-
TACGTGTACCACATGAAGCCG-39. The PCR products were
cloned into a NdeI/HindIII-digested pET-22b vector to obtain
pET-GRIM-19-Flag.
siRNA
The STAT3 siRNA sequence was: 59- CCAACGACCUG-
CAGCAAUAUU-39. The GRIM-19 siRNA sequence was: 59-
GCUUCAUGUGGUACACGUATT-39. In addition, an siRNA
with a random sequence (59- UUCUCCGAACGUGUCACG-
UTT-39) was used as the scrambled control. All of the plasmids
were confirmed by DNA sequencing.
Reverse transcription and quantitative PCR
One microgram total RNA extracted from tissues or cells was
converted to cDNA using Superscript III reverse transcriptase
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(Sigma) was conducted using the primer sets indicated in Table S1.
Immunoblotting
Proteins were transferred to Polyvinylidene fluoride (PVDF)
membranes and probed with the indicated primary antibodies.
GAPDH, p21, STAT3, pY-STAT3, p27 antibodies were
purchased from Cell Signaling. GRIM-19, Ubiquitin, PARP,
Caspase-3 and p53 antibodies were from Santa Cruz. PUMA,
Flag, His, E6AP antibodies were from Sigma. GST antibody was
from GE Healthcare. Membranes were then incubated with a
1:5000 dilution of a peroxidase-conjugated corresponding second-
ary antibody (Sigma). Blots were developed using an Enhanced
Chemiluminescence kit (Pierce).
Luciferase assays
Briefly, pGL3-P53-Luc and Renilla luciferase (internal control)
plasmids were co-transfected into cells. Luciferase activity was
determined using a dual-luciferase reporter assay kit (Promega).
The p53-Luc plasmid contains a 676 bp fragment of the human
p53 promoter (from +29 to 2704 bp). The p53- luciferase activity
was normalized to that of Renilla luciferase (internal control). The
data represent at least three independent experiments. Triplicate
samples were analyzed in each experiment,
Determination of p53 half-life
After overnight growth in complete RPMI-1640, cells (2610
6)
were treated with 100 mg/ml CHX (Sigma) for the indicated times,
washed with ice-cold 16PBS and lysed in RIPA buffer. Equal
quantity of protein from each sample was subjected to immunoblot-
ting band. The intensities of p53 protein and GAPDH were
quantified and the ratio was plotted as a percentage of remaining
p53. Triplicate samples were analyzed in each case; and the average
of three experiments was used to calculate the half-life of p53.
Synchronization and cell cycle analyses
The cells grown in serum-rich medium were synchronized by
incubating with 2.5 mM of thymidine (Sigma) for 18 h. Medium
was changed and they were grown for additional 8 h, after which
they were once again synchronized by incubating with 2.5 mM
thymidine for a further 18 h. At the end of synchronization, cells
were washed and cultured in a fresh serum-rich medium for the
indicated periods. They were then stained with Propidium Iodide
(BD Biosciences) and analyzed by flow cytometry.
MTT assay
Cells (2610
3/well) were seeded into a 96-well plate and
incubated at 37uC and growth was measured by adding 20 mlo f
MTT (5 mg/ml) into the culture medium. MTT reduction was
quantified using a plate reader. All assays were performed in
triplicate, and the data are presented as the mean 6 SD.
Transmission electron microscopy
For the morphologic studies, 1610
7 cells were fixed with 2.5%
glutaraldehyde in 0.1 mol/L phosphate-buffered saline (PBS),
post-fixed with 1% osmium tetroxide, and embedded in Epon
according to routine techniques. Thin sections were mounted on
nickel grids and examined by transmission electron microscopy
after staining with uranylacetate and lead citrate.
Coimmunoprecipitation
Clarified cellular lysates were incubated with the indicated
primary antibodies or normal mouse IgG (Santa Cruz) for 2 h at
4uC followed by the addition of Protein G-agarose beads for 2 h at
4uC. The bound complexes were then washed thrice with RIPA
buffer and separated by SDS-PAGE. Immunoblotting was
performed as described above.
In vitro translation
In vitro translation was performed using the TNT Quick Coupled
Transcription/Translation System (Promega) following the man-
ufacturer’s protocol. Briefly, 1 mg of plasmids were incubated with
25 ml of wheat germ extracts, 2 ml reaction buffer, 1 ml RNA
polymerase (T7), 0.5 ml 1 mM amino acid mixture minus leucine,
0.5 ml 1 mM amino acid mixture minus methionine, 1 ml
ribonuclease inhibitor, 1 ml transcend
TM tRNA at 30uC for
90 min. Nuclease-free water was added to a final volume of 50 ml.
GST pull-down
The recombinant proteins were expressed in E.coli BL21 strain
and were affinity purified with glutathione-Sepharose 4B resin (GE
Healthcare). For pull-down assays, 10 mg of GST or GST fusion
proteins were immobilized on glutathione-agarose for 2 h at 4uC
and were washed with cold PBS containing 1% TritonX-100. The
GST protein immobilized on glutathione-agarose was then
incubated with the cell lysates from E. coli BL21 strains expressing
Flag-tagged or His-tagged protein at 4uC overnight and
subsequently washed with cold 16PBS containing 1% TritonX-
100. The bound proteins were eluted and subjected to Western
blotting with the indicated antibodies.
In vivo ubiquitination assays
Cells were treated with the proteasome inhibitor MG-132
(20 mM; Calbiochem) for the indicated times, Cell extract (1 mg)
from each sample was immunoprecipitated with anti-ubiquitin or
the indicated specific antibody followed by Protein G agarose.
After washing with RIPA buffer, the immunocomplexes were
resolved by SDS-PAGE, Western blotted and probed with a
monoclonal anti-ubiquitin antibody.
In vitro ubiquitination assays
GST, GST-GRIM-19 were expressed in E.coli BL21 and
purified. Wild-type E6AP and dominant mutant C840A E6AP
were translated in wheat germ extracts with pCMV6-XL5-E6AP-
III and pET- C840A-E6AP respectively. To assess the in vitro
autoubiquitination of E6AP, the assays were performed in 30 ml
ubiquitination assay buffer (50 mM Tris-HCl ph8.0, 50 mM
NaCl, 1 mM dithiothreitol, 5 mM MgCl2, 3 mM ATP), with
0.25 mg of E1, 0.25 mg of UbcH5c (E2), 10 mg of ubiquitin (all
from Boston Biochem, Cambridge, Massachusetts, USA), 10 ml
translated E6AP (wild-type or C840A mutant) in wheat germ
extracts and 1.5 mg of GST or GST-GRIM-19. Samples were
incubated at 30uC for 2 h and reactions were terminated with
25 mM EDTA before Western blotting with anti-Ubiquitin
antibody.
Statistical analysis
The SPSS13.0 software package (SPSS, Inc, Chicago, IL) was
used for all statistical analyses. Statistical significance was
evaluated using the Student’s t-test for paired comparison with a
p value of ,0.05 considered statistically significant.
Supporting Information
Figure S1 GRIM-19 did not induce p53 protein accu-
mulation in non- E6-harboring cells. Cell lysates from
HO8910 or A549 cells with overexpression GRIM-19 together
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analysis.
(TIF)
Figure S2 GRIM-19 did not bind to mutant CA E6AP in
vitro. GST pull-down experiments were performed to examine
the interaction of GST-fused mutant CA E6AP with Flag-tagged
GRIM-19 protein in vitro.
(TIF)
Figure S3 GRIM-19-induced p53 protein accumulation
is independent of STAT3. (A) HeLa and SiHa cells were
transfected with either control siRNA or STAT3 siRNA. Forty-
eight hours later, cell lysates were prepared and subjected to
western blot analysis with the indicated antibodies. (B) HeLa and
SiHa cells were transfected with either STAT3C,STAT3DN
expression vectors or the control vector. Forty-eight hours later,
cell lysates were prepared and subjected to western blot analysis
with the indicated antibodies.
(TIF)
Table S1 List of oligonucleotides used in this study.
(DOC)
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